847358-98-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethylamino)-4-fluoro-4-methylpentanoic acid is used as a building block for more complex molecules due to its unique structure and properties. It may serve as a key component in the development of new pharmaceuticals, given its potential to be incorporated into various drug candidates.
Used in Chemical Research:
In the field of chemical research, (S)-2-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethylamino)-4-fluoro-4-methylpentanoic acid is used as a pharmacophore for drug development. Its distinct structural features make it a valuable compound for studying the interactions between molecules and their biological targets, which can lead to advancements in medicinal chemistry and the discovery of novel therapeutic agents.
Further research and analysis are required to fully understand the potential uses and effects of (S)-2-((S)-1-(4-broMophenyl)-2,2,2-trifluoroethylaMino)-4-fluoro-4-Methylpentanoic acid, as its specific applications may depend on the context of its incorporation into larger molecular structures or its interaction with biological systems.

Upstream product

• 603142-95-6 (2S)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]amino}-4-fluoro-4-methylpentan-1-ol 

Downstream Products

• 1159488-95-5 (S)-2-[(S)-1-(4-bromo-phenyl)-2,2,2-trifluoro-ethylamino]-4-fluoro-4-methyl-pentanoic acid [(S)-1-cyano-2-(4-cyano-2-fluoro-phenyl)-ethyl]-amide 
• 847361-73-3 N²-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-4-fluoro-N¹-[(2R,3S)-2-methyl-4-oxotetrahydrofuran-3-yl]-L-leucinamide 

Relevant academic research and scientific papers

Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease

Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease is described. The identified inhibitors bearing an amino nitrile warhead in P1 exhibit low nanomolar in vitro potency against cruzipain. Further SAR in P2 por

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is i

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

CATHEPSIN INHIBITORS

This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.